184913-19-7

Usage

Uses

Used in Pharmaceutical Research and Drug Discovery:
Isoquinoline, 3,4-dihydro-7-methoxyis used as a research compound for its potential medicinal properties. It has been studied for its potential as a therapeutic agent in the treatment of various diseases, including cancer and neurodegenerative disorders.
Used in Synthesis of Other Organic Compounds:
Isoquinoline, 3,4-dihydro-7-methoxyis also used as a precursor for the synthesis of other organic compounds. Its unique structure and functional groups make it a valuable building block in the development of new chemical entities with potential applications in various industries.

InChI:InChI=1/C10H11NO/c1-12-10-3-2-8-4-5-11-7-9(8)6-10/h2-3,6-7H,4-5H2,1H3

Upstream product

• 1393714-83-4 C₁₇H₁₉NO₃S 
• 141666-92-4 4-methyl-N-[2-(4-methoxyphenyl)ethyl]benzenesulfonamide 
• 55-81-2 4-Methoxyphenethylamine 
• 56100-69-7 N-[2-(4-methoxyphenyl)ethyl]formamide 

Downstream Products

• 184913-11-9 9-methoxy-2-(o-tolyl)-5,6-dihydroimidazo[2,1-a]isoquinoline 

Relevant academic research and scientific papers

Regioselective assembly of 3,4-dihydroisoquinoline derivatives

A facile two-step sequence (9→10→1) of regioselective assembly of 3,4-dihydroisoquinoline derivatives 1 is reported. The halogen derivatives provide opportunity for Suzuki, Buchwald, and related coupling reactions useful for expanding the scaffold and lea

Identification and characterization of m4 selective muscarinic antagonists

Our interest in the area of m4 muscarinic antagonists has led us to study a series of benzoxazine isoquinolines. One of the most potent and selective compounds of this series is example 1 with an IC50 value of 90.7nM at m4 receptors, and 72-fold (m1), 38-fold (m2), 10-fold (m3), and 82- fold (m5) more selective compared to the other receptors. The synthesis and receptor binding affinity of analogs of 1 are reported.

Decahydro-8H-isoquino[2,1-g][1,6]naphthyridine and decahydrobenzo[a]pyrrolo [2,3-e]quinolizine derivatives

Compounds of the formula STR1 wherein: m is an integer of 1-6;n is an integer of 1 or 2;X and Y are independently hydrogen; hydroxy; lower alkyl; lower alkoxy; or halo; or X and Y when adjacent and taken together are methylenedioxy or ethylene-1,2-dioxy;R is STR2 wherein: R 1 and R 2 are independently hydrogen or lower alkyl, or when taken together with the carbon to which they are attached are cycloalkyl;R 3 is hydrogen, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl or halo; and STR3 and pharmaceutically acceptable acid addition salts thereof. The compounds and salts exhibit useful pharmacological properties, including selective α 2 -adrenoceptor antagonist properties and 5-HT 1A receptor partial agonist properties, and are particularly useful for the treatment of sexual dysfunction, depression and anxiety.

Process for the preparation of (8As,12AS,13AS)-decahydroisoquino ((2,1-G) (1,6)-naphthyridin-8-one derivatives

The invention provides a process for preparing single enantiomers of compounds represented by the formula: STR1 and chiral acid addition salts thereof; wherein: X and Y are independently hydrogen; lower alkyl; lower alkoxy; or halo; or X and Y taken together is methylenedioxy or ethylene-1,2-dioxy; which includes reduction of a compound represented by the formula: STR2 to give a mixture of stereoisomers represented by the formula: STR3 wherein each wavy line independently represents a bond in either the α or β position; followed by dissolving the mixture of stereoisomers and a chiral resolving acid in a suitable solvent and allowing the solution to crystallize, giving a salt of the desired enantiomer.

Decahydro-8H-isoquino[2,1-g][1,6]naphthyridine and decahydrobenzo[a]pyrrolo[2,3-e]quinolizine derivatives

Compounds of the formula ψψ ψwherein:ψ X and Y are independently hydrogen; hydroxy; lower alkyl of 1-6 carbon atoms; lower alkoxy of 1-6 carbon atoms; or halo; or X and Y when adjacent and taken together are methylenedioxy or ethylene-1,2-dioxy;ψ R is lower alkyl of 1-6 carbon atoms; cycloalkyl of 3-8 carbon atoms; phenyl or phenyl lower alkyl in which any phenyl group may be optionally substituted by one or two substituents chosen from the group consisting of halo, lower alkyl of 1-4 carbon atoms and lower alkoxy of 1-4 carbon atoms; or -ANHSO2R1; wherein A is lower alkylene of 1-6 carbon atoms; and R1 is lower alkyl of 1-6 carbon atoms or -NRyR3; whereinψ Ry and R3 are independently hydrogen or lower alkyl of 1-6 carbon atoms, or Ry and R3 taken together are cycloalkyl of 3-8 carbon atoms; andψ n is 1 or 2;ψ and the pharmaceutically acceptable salts thereof, are useful as à2-adrenoceptor antagonists, in particular as peripherally selective à2 -adrenoceptor antagonists.ψ